Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Common Equity (2019 - 2025)

Legend Biotech filings provide 7 years of Common Equity readings, the most recent being $1.0 billion for Q4 2025.

  • On a quarterly basis, Common Equity fell 3.7% to $1.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 billion, a 3.7% decrease, with the full-year FY2025 number at $1.0 billion, down 3.7% from a year prior.
  • Common Equity hit $1.0 billion in Q4 2025 for Legend Biotech, down from $1.0 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.4 billion in Q2 2023 to a low of $206451.0 in Q1 2021.
  • Median Common Equity over the past 5 years was $1.0 billion (2025), compared with a mean of $870.9 million.
  • Biggest five-year swings in Common Equity: surged 358900.44% in 2022 and later fell 17.63% in 2024.
  • Legend Biotech's Common Equity stood at $765.9 million in 2021, then fell by 2.82% to $744.3 million in 2022, then surged by 68.12% to $1.3 billion in 2023, then decreased by 16.84% to $1.0 billion in 2024, then dropped by 3.7% to $1.0 billion in 2025.
  • The last three reported values for Common Equity were $1.0 billion (Q4 2025), $1.0 billion (Q3 2025), and $1.0 billion (Q2 2025) per Business Quant data.